Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Towards personalized dosing of natalizumab in multiple sclerosis
2016-000345-31Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Amsterdam University Medical Center. Primary endpoint: Formation of new gadolinium-enhancing T1-weighted lesions. Started Apr 2016; status: active.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2016-000345-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000345-31.